Blueprint Medicines is a precision medicine company focused on developing targeted therapies for patients with cancer and rare diseases. The company uses genomics and computational biology to identify and develop drugs that target specific genetic drivers of disease. Blueprint has successfully brought multiple drugs to market, including treatments for gastrointestinal stromal tumors and systemic mastocytosis. The company represents the advancement of personalized medicine and targeted cancer therapies.
Blueprint Medicines has received investment from 2 venture capital firms.
Precision medicine company developing targeted therapies for cancer and rare diseases using genomics-based drug discovery.
Blueprint Medicines has received investment from Polaris Partners, Third Rock Ventures. These venture capital firms and investors provide both capital and strategic support.
Blueprint Medicines has raised $676M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Blueprint Medicines was founded in 2011 and is headquartered in Cambridge, MA.
Blueprint Medicines operates in the Biotech sector. Precision medicine company developing targeted therapies for cancer and rare diseases using genomics-based drug discovery.
